» Articles » PMID: 25776995

Outcome After Surgical Resection for Duodenal Adenocarcinoma in the UK

Overview
Journal Br J Surg
Specialty General Surgery
Date 2015 Mar 18
PMID 25776995
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Factors influencing long-term outcome after surgical resection for duodenal adenocarcinoma are unclear.

Methods: A prospectively created database was reviewed for patients undergoing surgery for duodenal adenocarcinoma in six UK hepatopancreaticobiliary centres from 2000 to 2013. Factors influencing overall survival and disease-free survival (DFS) were identified by regression analysis.

Results: Resection with curative intent was performed in 150 (84·3 per cent) of 178 patients. The postoperative morbidity rate for these patients was 40·0 per cent and the in-hospital mortality rate was 3·3 per cent. Patients who underwent resection had a better median survival than those who had a palliative surgical procedure (84 versus 8 months; P < 0·001). The 1-, 3- and 5-year overall survival rates for patients who underwent resection were 83·9, 66·7 and 51·2 per cent respectively. Median DFS was 53 months, and 1- and 3-year DFS rates were 80·8 and 56·5 per cent respectively. Multivariable analysis revealed that node status (hazard ratio 1·73, 95 per cent c.i. 1·07 to 2·79; P = 0·006) and lymphovascular invasion (hazard ratio 3·49, 1·83 to 6·64; P = 0·003) were associated with overall survival.

Conclusion: Resection of duodenal adenocarcinoma in specialist centres is associated with good long-term survival. Lymphovascular invasion and nodal metastases are independent prognostic indicators.

Citing Articles

Long-term survival outcomes of duodenal adenocarcinoma: A cohort study with 15-year single-center experience.

Xie Q, Long L, Luo Y, Lu M, Ming W, Zhao L World J Gastrointest Surg. 2025; 17(2):101365.

PMID: 40061982 PMC: 11886021. DOI: 10.4240/wjgs.v17.i2.101365.


Development and external validation of a machine learning-based model to predict postoperative recurrence in patients with duodenal adenocarcinoma: a multicenter, retrospective cohort study.

Liu X, Xiao Q, Gu Z, Wu X, Yuan C, Tang X BMC Med. 2025; 23(1):98.

PMID: 39984949 PMC: 11846245. DOI: 10.1186/s12916-025-03912-7.


Efficacy of lymph node dissection for duodenal cancer according to the lymph node station.

Miura Y, Ohgi K, Ashida R, Yamada M, Otsuka S, Sasaki K Ann Gastroenterol Surg. 2024; 8(1):51-59.

PMID: 38250683 PMC: 10797846. DOI: 10.1002/ags3.12731.


Impact of extra-ampullary duodenal adenocarcinoma subtypes on surgical and oncological outcomes following pancreaticoduodenectomy.

De Pastena M, Zingaretti C, Paiella S, Guerriero M, De Santis N, Luchini C Updates Surg. 2023; 76(1):87-95.

PMID: 38093152 DOI: 10.1007/s13304-023-01688-0.


A rare case of duodenal adenocarcinoma.

Tuan H, Lieu D, Anh T, Tuan H, Ly T, Kha V Radiol Case Rep. 2023; 18(12):4400-4403.

PMID: 37829165 PMC: 10565683. DOI: 10.1016/j.radcr.2023.09.037.